Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2011, Vol. 16 ›› Issue (9): 998-1001.

Previous Articles     Next Articles

Comparasion of anti-platelet aggregation and PAF decrease effect among EGB,Asprin and Plavix

WANG Ru-wei1, LV Shen1, HUANG Li1, XU Lu2, DONG Zhi2   

  1. 1Zhejiang Chinese Medicine and Natural Drug Research Institute, Zhejiang Provinical Key Laboratory of Traditional Chinese Medicine Pharmacecutical Techonology, Hangzhou 310052, Zhejiang, China;
    2Chongqing Medical University, Chongqing 400016, China
  • Received:2011-07-07 Revised:2011-08-25 Online:2011-09-26 Published:2011-10-11

PDF (PC)

346

Abstract: AIM: To compare the effect of anti-platelet aggregation function and the PAF's contect among the EGB preparation,Asprin and Plavix. METHODS: Experiment in vivo was used to observe the platelet aggregation effect induced by AA,ADP,PAF among the EGB preparation,Asprin,Plavix. RESULTS: Compared with saline group,EGB could significantly inhibit the platelet aggregation induced by AA,ADP,PAF (P<0.05, P<0.01), reduce the PAF's content in serum(P<0.05); Asprin could significantly inhibit the platelet aggregation induced by AA (P<0.01); Plavix could significantly inhibit the platelet aggregation induced by ADP (P<0.01); Asprin and Plovix had no significantly different on PAF's content(P>0.05). CONCLUSION: EGB has anti-platelet aggregation function, and can reduce the PAF's content in serum.

Key words: EGB preparation, Anti-platelet aggregation, Platelet activating factor

CLC Number: